Skip to main content
. 2019 May 1;36(3):243–250. doi: 10.36141/svdld.v36i3.8219

Table 4.

Comparison of demographic and clinical characteristics of PSV patients between ever and never smokers

Variables Ever smokers (N=27) Never smokers (N=99) P*
Age 54.85±13.9 46.99±16.8 0.028
Sex (Female/Male) 3/24 67/32 0.0001
General symptoms (%) 19 (70.4) 55 (55.6) 0.128
Cutaneous involvement/Mucous membranes (%) 12 (44.4) 45 (45.6) 0.517
Ophthalmic involvement (%) 3 (11.1) 7 (7.1) 0.356
Ears, nose, throat involvement (%) 9 (33.3) 17 (17.1) 0.068
Pulmonary involvement (%) 8 (29.6) 17 (17.2) 0.123
Cardiovascular system involvement (%) 4 (14.8) 15 (15.2) 0.602
Abdominal involvement (%) 2 (7.4) 4 (4.0) 0.389
Renal involvement (%) 11 (40.7) 29 (29.3) 0.201
Nervous system involvement (%) 9 (33.3) 32 (32.3) 0.147
BVAS at the baseline 13.96±8.9 9.69±5.8 0.020
VDI at the baseline 0 (0-3) 0 (0-3) 0.632
VDI at the last visit 0 (0-3) 1 (0-4) 0.595
Patients with disease in remission 23 (33.3) 89 (35.5) 0.540

PSV: primary systemic vasculitides; BVAS: Birmingham Vasculitis Activity Score; VDI: Vasculitis Damage Index.

Data were displayed as numbers (percentages), means ± SD, or median (Min-Max), as appropriate.

P< 0.05 was considered significant.

* P values indicate comparison between groups (Chi squared, Independent-sample t test or Mann–Whitney U test, as appropriate)